
#211 Breaking Down MASLD vs. MASH and the MAESTRO-NASH & ESSENCE Trials: Beyond Journal Club Segment
Core IM Team... · 35:48 · 7,338 پلے
تفصیل
MASLD affects nearly one in three adults worldwide, yet many patients remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening? When is a FIB-4 enough, and when should we move to elastography or hepatology referral? And are we finally entering an era where we can meaningfully treat MASH?In this Beyond Journal Club episode, we unpack the evolving language of steatotic liver disease and take a close look at two major trials: MAESTRO-NASH studying resmetirom, the first FDA-approved liver-directed therapy for MASH, and ESSENCE, evaluating semaglutide in biopsy-confirmed disease.Along the way, we explore what these biopsy-based histologic endpoints really mean, why placebo responses were surprisingly high, and whether improvements in steatohepatitis and fibrosis will ultimately translate into better clinical outcomes for patients.This episode is for clinicians trying to understand where the field is headed, which patients deserve closer attention, and how metabolic liver disease is increasingly becoming part of everyday primary care and hospital medicine.🔹Sponsor: Oakstone CMEUse the code "CORE25" for 25% off: https://www.coreimpodcast.com/MKSAP 🔹Transcript and Shownotes: 01:57 | Understanding MASLD as a Systemic Disease 05:45 | MASLD vs MASH vs Met-ALD: Spectrum Steatotic Liver Disease 08:55 | How to Screen for Fibrosis (FIB-4 & FibroScan) 16:15 | Lifestyle Treatment & Weight Loss Targets 19:00 | ESSENCE Trial: Semaglutide for MASH 21:58 | MAESTRO-NASH Trial: Resmetirom 27:27 | Future Treatments for MASH 30:51 | Key Takeaways for Clinicians Tags: CoreIM, Internal Medicine, Medical Education, Hepatology, Fatty Liver Disease, Metabolic Dysfunction Associated Steatohepatitis, Nonalcoholic Fatty Liver Disease, Liver FibrosisFind the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840Our Sponsors:* Check out CovePure and use my code CovePure.com/coreim for a great deal: https://covepure.com* Check out ElevenRe
More By Core IM Team...
- 1
#205 Nutrition Studies, Coffee and the CRAVE Trial: Beyond Journal Club with the NEJM Group
Core IM Team... · 5,114 پلے · 35:01
- 2
#213 Hypertension First-Line Medications Troubleshooting | Bread & Butter Series
Core IM Team... · 10,028 پلے · 34:54
- 3
#203 POCUS for AKI & Dialysis | Real Cases That Changed Management
Core IM Team... · 7,215 پلے · 31:18
- 4
#214 Hyponatremia Management: A Core IM Classic
Core IM Team... · 4,703 پلے · 47:06
- 5
#201: Dementia Part 1: Gray Matters Segment
Core IM Team... · 8,798 پلے · 47:18
- 6
#202 Dementia Part 2: Gray Matters Segment
Core IM Team... · 9,407 پلے · 48:22
- 7
#200: Insulin and QWINT-1 Trial in T2DM: Beyond Journal Club Segment with NEJM Group
Core IM Team... · 8,555 پلے · 29:07
- 8
#199 Privacy & Confidentiality: At the Bedside Segment
Core IM Team... · 9,629 پلے · 38:37
- 9
#206 Eosinophilia: 5 Pearls Segment
Core IM Team... · 8,796 پلے · 44:20
- 10
#194: Severe Hypertriglyceridemia: 5 Pearls Segment
Core IM Team... · 6,087 پلے · 39:26
آپ کو یہ بھی پسند آ سکتے ہیں
- 1
البمFull Episodes | Pablo Torre Finds Out
PABLO TORRE FINDS OUT · 7,723 پلے
- 2
البمThe Prancing Pony Podcast
The Prancing Pony Podcast... · 5,419 پلے
- 3
البمQuits the Band
Neon Bone · 8,796 پلے
- 4
البمETHIOPIA
HAILEKALL · 6,347 پلے
- 5
البمSatellite
Creative Culture · 9,889 پلے
- 6
البمThe FreezING KniGht
M3THIS · 8,838 پلے
- 7
البمPulkit Sharma
Pulkit Sharma · 1,220 پلے
- 8
البمAngkatan Udara
Angkatan Udara · 2,100 پلے
- 9
البمSlow Hollows
Slow Hollows · 5,460 پلے
- 10
البمLord of The Mysteris - Vol. 01
7,150 پلے
- 11
البمCiaran Austin
Ciaran Austin · 3,853 پلے
- 12
البمGreatest Hits
Manfred Mann · 9,776 پلے